comparemela.com

Latest Breaking News On - Midwest business group on health - Page 5 : comparemela.com

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

New yorkUnited statesUnited kingdomAntonio ciacciaRichard gonzalezMadelaine feldmanCora opsahlMichael thompsonKeith athowJuliana reedKaiser permanenteGreg bakerCoherus biosciencesMary beth langRachel shubertSiddharth singh

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

United statesNew yorkUnited kingdomGreg bakerCoherus biosciencesRachel shubertMary beth langJuliana reedKaiser permanenteKeith athowMichael thompsonKevin aliPaul holmesSiddharth singhMark cubanAlex jung

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

New yorkUnited statesUnited kingdomKevin aliPaul holmesKeith athowAntonio ciacciaMary beth langKaiser permanenteGreg bakerMark cubanRichard gonzalezRachel shubertSiddharth singhAlex jungJuliana reed

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

United statesNew yorkUnited kingdomKaiser permanenteMary beth langRachel shubertPaul holmesRichard gonzalezAlex jungSiddharth singhAntonio ciacciaMichael thompsonGreg bakerMadelaine feldmanCoherus biosciencesMark cuban

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

United kingdomUnited statesNew yorkCoherus biosciencesMichael thompsonMadelaine feldmanCora opsahlAlex jungJuliana reedRachel shubertSiddharth singhRichard gonzalezGreg bakerMark cubanAntonio ciacciaMary beth lang

vimarsana © 2020. All Rights Reserved.